NASDAQ:SABS SAB Biotherapeutics Q3 2026 Earnings Date & Estimates $3.14 -0.17 (-5.00%) As of 03:52 PM Eastern This is a fair market value price provided by Massive. Learn more. SAB Biotherapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from SAB Biotherapeutics in Q3 2026SAB Biotherapeutics is expected to post earnings of -$0.27 per share on revenue of $125 thousand. In the same quarter a year earlier SAB Biotherapeutics reported -$0.21 per share. SAB Biotherapeutics last reported on August 6, 2026, posting -$0.28 per share and beating the -$0.2830 consensus estimate. SAB Biotherapeutics has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.27Expected Revenue$125 thousandPrior-Year EPS-$0.21Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.28 (Beat by +$0.0030)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report SAB Biotherapeutics Q3 2026 Earnings FAQ When does SAB Biotherapeutics report Q3 2026 earnings? SAB Biotherapeutics (NASDAQ:SABS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is SAB Biotherapeutics' Q3 2026 earnings call? SAB Biotherapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for SAB Biotherapeutics? Analysts expect SAB Biotherapeutics to post earnings of -$0.27 per share for Q3 2026. How much revenue is SAB Biotherapeutics expected to report? The consensus revenue estimate for SAB Biotherapeutics is $125 thousand for Q3 2026. SAB Biotherapeutics Earnings HeadlinesSAB Biotherapeutics (SABS) Expected to Post Earnings on ThursdayOctober 31 at 2:26 AM | americanbankingnews.comSAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ETOctober 29, 2026 | globenewswire.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.November 3 at 1:00 AM | Digest Publishing (Ad)SAB Biotherapeutics Says SAB-142 Receives FDA Fast Track Designation in Type 1 DiabetesOctober 14, 2026 | finance.yahoo.comSAB BIO to Participate in Chardan 10th Annual Healthcare ConferenceOctober 14, 2026 | globenewswire.comSAB Biotherapeutics, Inc. Receives FDA Fast Track Designation For SAB-142 In Stage 3 Type 1 DiabetesOctober 13, 2026 | marketscreener.comMSee More SAB Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email. Email Address About SAB BiotherapeuticsSAB Biotherapeutics (NASDAQ:SABS) is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota. SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources. The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases. Its research and development activities have included collaborations with government agencies, academic institutions and pharmaceutical organizations. SAB Biotherapeutics became a publicly traded company on Nasdaq through a business combination completed in 2021.View SAB Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestApple's Earnings Beat Comes With a Catch for Investors Heading Into the HolidaysRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
